Related references
Note: Only part of the references are listed.Reversal of siRNA - mediated gene silencing in vivo
Ivan Zlatev et al.
NATURE BIOTECHNOLOGY (2018)
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
Maja M. Janas et al.
NATURE COMMUNICATIONS (2018)
An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria
Abigail Liebow et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GaINAc-siRNA Conjugate
Tracy S. Zimmermann et al.
MOLECULAR THERAPY (2017)
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
K. J. Pasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Impact of Oligonucleotide Structure, Chemistry, and Delivery Method on In Vitro Cytotoxicity
Maja M. Janas et al.
NUCLEIC ACID THERAPEUTICS (2017)
Assessment of the Effects of 2'-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates
Scott P. Henry et al.
NUCLEIC ACID THERAPEUTICS (2017)
The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2017)
Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia
Sabine Sewing et al.
PLOS ONE (2017)
Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts
Sebastien A. Burel et al.
NUCLEIC ACIDS RESEARCH (2016)
Rationally designed siRNAs without miRNA-like off-target repression
Heeyoung Seok et al.
BMB REPORTS (2016)
Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside
Timofei S. Zatsepin et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2016)
OSWG Recommendations for Genotoxicity Testing of Novel Oligonucleotide-Based Therapeutics
Cindy L. Berman et al.
NUCLEIC ACID THERAPEUTICS (2016)
Exposure to siRNA-GalNAc Conjugates in Systems of the Standard Test Battery for Genotoxicity
Maja M. Janas et al.
NUCLEIC ACID THERAPEUTICS (2016)
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
Alfica Sehgal et al.
NATURE MEDICINE (2015)
Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides
Jeffery A. Engelhardt et al.
TOXICOLOGIC PATHOLOGY (2015)
Abasic pivot substitution harnesses target specificity of RNA interference
Hye-Sook Lee et al.
NATURE COMMUNICATIONS (2015)
Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification
Amy Chan et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Antisense Oligonucleotide Therapies: The Promise and the Challenges from a Toxicologic Pathologist's Perspective
Kendall S. Frazier
TOXICOLOGIC PATHOLOGY (2015)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Sequence motifs associated with hepatotoxicity of locked nucleic acid-modified antisense oligonucleotides
Andrew D. Burdick et al.
NUCLEIC ACIDS RESEARCH (2014)
Species-specific Inflammatory Responses as a Primary Component for the Development of Glomerular Lesions in Mice and Monkeys Following Chronic Administration of a Second-generation Antisense Oligonucleotide
Kendall S. Frazier et al.
TOXICOLOGIC PATHOLOGY (2014)
Comparison of Hepatic Transcription Profiles of Locked Ribonucleic Acid Antisense Oligonucleotides: Evidence of Distinct Pathways Contributing to Non-target Mediated Toxicity in Mice
Satoko Kakiuchi-Kiyota et al.
TOXICOLOGICAL SCIENCES (2014)
Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
Martin A. Maier et al.
MOLECULAR THERAPY (2013)
Hepatotoxic Potential of Therapeutic Oligonucleotides Can Be Predicted from Their Sequence and Modification Pattern
Peter H. Hagedorn et al.
NUCLEIC ACID THERAPEUTICS (2013)
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo
Muthusamy Jayaraman et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing
Glen F. Deleavey et al.
CHEMISTRY & BIOLOGY (2012)
miR-122 regulates hepatic lipid metabolism and tumor suppression
Jessica Wen et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver
Shu-hao Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Silencing disease genes in the laboratory and the clinic
Jonathan K. Watts et al.
JOURNAL OF PATHOLOGY (2012)
Chemical Modification Study of Antisense Gapmers
Robert Stanton et al.
NUCLEIC ACID THERAPEUTICS (2012)
Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2
Eckhardt S. Ferdinandi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs
Narendra Vaish et al.
NUCLEIC ACIDS RESEARCH (2011)
A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects
Jesper B. Bramsen et al.
NUCLEIC ACIDS RESEARCH (2010)
Diagnostic Performance of Traditional Hepatobiliary Biomarkers of Drug-Induced Liver Injury in the Rat
Daniela Ennulat et al.
TOXICOLOGICAL SCIENCES (2010)
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
Eric E. Swayze et al.
NUCLEIC ACIDS RESEARCH (2007)
2 '-modified oligonucleotides for antisense therapeutics
Thazha P. Prakash et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
Widespread siRNA off-target'' transcript silencing mediated by seed region sequence complementarity
Aimee L. Jackson et al.
RNA (2006)
3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets
A Birmingham et al.
NATURE METHODS (2006)
Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response independent of toll-like receptor 9 or myeloid differentiation factor 88
JJ Senn et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality
J Elmen et al.
NUCLEIC ACIDS RESEARCH (2005)
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
J Soutschek et al.
NATURE (2004)
Expression profiling reveals off-target gene regulation by RNAi
AL Jackson et al.
NATURE BIOTECHNOLOGY (2003)
Expression of a functional asialoglycoprotein receptor in human renal proximal tubular epithelial cells
YYT Seow et al.
NEPHRON (2002)
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
SM Elbashir et al.
NATURE (2001)
Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA
DA Braasch et al.
CHEMISTRY & BIOLOGY (2001)
Phosphorothioate oligodeoxynucleotides: What is their origin and what is unique about them?
F Eckstein
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2000)
Share Paper
